Published on : Jun 07, 2016
The World Health Organization explains pharmacovigilance as an array of activities and sciences that are involved in the understanding, examination, detection, and prevention of the serious consequences of drug intake. After the thalidomide disaster was found out in 1961, the WHO had initiated their own Programme for International Drug Monitoring, which is considered a major regulatory body in the global market for pharmacovigilance services. By the end of 2010, 13 nations had already become a part of the pharmacovigilance programme. Their primary aim is to improve the detection rates of patient care medicines, in addition to imparting valuable information to the public health programmes for the countries involved. The idea is to get the maximum awareness rates going on for the various threats faced through the consumption of certain drugs.
DIA India Conference a Place of Experts and Industry Experts
DIA India had recently ended a conference that was scheduled for two days. The primary topic of discussion was the incoming waves of change in the e-pharmacovigilance section. The speakers during the conference reflected upon the various factors that are considered in the improvement of this market in India. The conference also scanned through the data on the E.U. application and submission procedures and their importance to pharmacovigilance.
On the first day there was panels in the discussion of the clinical trials industry in India and its current state. Panelists had also added the procedure that was currently being taken by the industry in order to increase growth rates.
In one of the many QnA sessions, one of the major points raised was the negative image created by the media regarding the clinical trials industry. It was opined that while negative images are being created to be revealed by the media, there has to be a balance in what the media shows. For instance, currnely no CRO from India has actually received any warning letters from the US FDA.